The incidence of acute anaesthetic-associated MH varied from 1 in 4000 to 1 in 250,000 anaesthetics over a 6.5-year period, depending on the details of the clinical definition of MH and the type of anaesthetic drugs to which the patient was exposed. It has been estimated that the prevalence of a genetic substrate responsible for susceptibility to MH is present in at least 1 in 3000 people. This is based in part on the observation of compound heterozygotes of ryanodine receptor gene type 1 (RYR1) variants that have been found in people susceptible to MH in Europe, North America, and Japan. RYR1 variants have also been found in families where MH events and deaths occurred in South America, South Africa, Australia, New Zealand, Korea, and China. However, RYR1 mutations may account for only 50% of MH cases, so measures of MH susceptibility prevalence obtained using RYR1 mutations alone are likely to be underestimates. The reported yields vary with the population selected and the details of the genetic test.
BMJ Best Practice is an evidence-based point of care tool for healthcare practitioners.
To continue reading and access all of BMJ Best Practice's pages you'll need to log in or start a free trial.
You can access through your institution if your hospital, university, trust or other institution provides access to BMJ Best Practice through either OpenAthens or Shibboleth.
Use of this content is subject to our disclaimer